statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR...

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases...

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KYTX stock, giving a Buy rating on March 26.
Thomas Smith has given his Buy rating due to a combination of factors...

Buy Rating Affirmed for Kyverna Therapeutics on Promising Early-Stage KYV-101 Results for MS Treatment

Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on Kyverna Therapeutics, Inc. (KYTX Research Report), retaining the price target...

Buy Recommendation: Kyverna Therapeutics' Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market Leadership

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With...

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results PR Newswire...

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Kyverna Therapeutics, Inc. (NASDAQ:KYTX  Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $25.09 and last traded at $25.16, with a volume...

Kyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $25.09

Kyverna Therapeutics (NASDAQ:KYTX  Get Free Report) quiet period is set to end on Tuesday, March 19th. Kyverna Therapeutics had issued 14,500,000 shares in its IPO on February 8th. The...

Kyverna Therapeutics, Inc.'s (NASDAQ:KYTX) Quiet Period To End  on March 19th

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kyverna Therapeutics, Stanford University to evaluate KYV-101 in MS

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis Kyverna Therapeutics and Stanford University Agree to...

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Watchers	91
52-Wk Low	$12.26
52-Wk High	$35.06

Volume	280,858.00
52-Wk High	$35.06
52-Wk Low	$12.26

KYTX Kyverna Therapeutics Inc.

About

Feed

News

Sentiment

Fundamentals